The present study of the regulatory T phenotype of Sézary cells led to the discovery of the expression of LRRC33 by Sézary cells. LRRC33 therefore appears as a diagnostic marker, for monitoring Sézary syndrome, and as a therapeutic target. Accordingly, the present invention relates to methods for the diagnosis and treatment of cutaneous T cell-lymphomas.